Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma
/in Dendritic Cells, Exosome, International Publications, Malignant Pleural MesotheliomaDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials
/in Dendritic Cells, Glioblastoma, International PublicationsExploiting dendritic cells in the development of cancer vaccines
/in Dendritic Cells, International PublicationsA review of dendritic cell therapy for cancer: progress and challenges
/in Dendritic Cells, International PublicationsImmunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials
/in Glioblastoma, International Publications, IOZK VeröffentlichungenTemperature matters! And why it should matter to tumor immunologists
/in Hyperthermia, International PublicationsVaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?
/in Dendritic Cells, International Publications, Multiple MyelomaDistinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes
/in Exosome, International PublicationsOncolytic viruses as therapeutic cancer vaccines
/in International Publications, Newcastle Disease Virus
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer